Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about skepticism towards a hair serum advertised on Instagram, with users doubting its effectiveness and one sharing a personal negative experience with the product.

The conversation is a humorous discussion on whether the historical figure Chairman Mao should have used finasteride for hair loss, with various users making light-hearted comments about his appearance and historical actions. Specific treatments mentioned include finasteride.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The conversation humorously discusses hair loss treatments like Minoxidil, Finasteride, and Dutasteride, and their effects on hair and muscle gains. Users debate effectiveness and side effects, mixing scientific approaches with jokes.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

The conversation revolves around how balding has made the original poster and others hyper-aware of other men's hairlines, often judging the severity of their hair loss and whether they've had treatments like hair transplants, minoxidil, or finasteride. Some participants express a need for therapy due to their obsession, while others joke about their newfound "expertise" in assessing hair loss.

The conversation is about men discussing their experiences with hair loss and their acceptance or resistance to it, mentioning treatments like finasteride and hair transplants. Some users express hope to maintain their hair while young, while others have accepted baldness or found confidence after shaving their heads.

Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.

The potential effectiveness of homemade topical spironolactone in treating hair loss, with studies suggesting it is more effective than finasteride and even minoxidil when used as monotherapy. The conversation also mentions that other anti-androgens are being developed which may soon hit the market.

A man felt insecure when his date touched his thinning hair, causing awkwardness. He uses finasteride and minoxidil for hair loss but still struggles with confidence.

A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.

The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.

The conversation is about differing experiences with finasteride for hair loss, with some users reporting side effects and others not, and the debate over the drug's safety and effectiveness. Specific treatments mentioned include finasteride, dutasteride, and topical finasteride.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.

A 20 year old male who is balding and considering switching to a biology/chemistry program in order to find a low-cost, accessible solution for hair loss. Replies discuss the merits of this idea as well as potential treatments such as Minoxidil, finasteride, RU58841, TM5614, and ADQ.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.

Many people feel self-conscious about hair loss during haircuts, with some using treatments like finasteride and minoxidil. Others cope by cutting their own hair or finding a trusted barber to manage thinning areas.

Late 20s woman struggles with worsening hair loss and tried various treatments without success. Now trying spironolactone and ketokonazole shampoo, hoping for improvement.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

The conversation is about enhancing dermarolling for hair loss by using topical peptides like tb-500 or GHK-Cu to aid in healing and hair growth, and whether anyone has experienced significant results from this method.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

The conversation discusses various treatments for hair loss, including minoxidil, finasteride, and topical dutasteride, with users debating their effectiveness and side effects. Despite the treatments, many believe androgenetic alopecia (AGA) ultimately prevails in the long term.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.